7/29/2019 Healthcare Sector in India Monthly Update September 2012 http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-september-2012 1/13 Healthcare Sector in India Monthly Update September 2012
7/29/2019 Healthcare Sector in India Monthly Update September 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-september-2012 1/13
Healthcare Sector in India
Monthly Update
September 2012
7/29/2019 Healthcare Sector in India Monthly Update September 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-september-2012 2/13
Top Story
348 drugs to come under NLEM
Indian government has for the first time decided to put a price ceiling on essential drugs that will bring relief to huge section of population. 348 such drugs have been identified by a
group of ministers, the proposal of which has been passed on 27th Sep 2012. Drugs that will
soon come under the National List of Essential Medicines (NLEM) include some of the most
critical disease medications like AIDS and cancer apart from a multitude of painkillers, anti‐
tuberculosis drugs, sedatives, lipid lowering agents and steroids. The identified drugs that
omprise 60% of domestic market will be sold at a price fixed by the government once it getsc
the approval of the cabinet.
The initiative by the Indian government is praise worthy but its speedy implementation is
what will bring out the true effectiveness of the plan. Unnecessary delays due to bureaucratic
involvement could ruin the impact of the initiative. Thus, the cabinet and group of ministersmust quicken the proposal assessment for mass benefit.
News Update
General
Electronic health cards to be launched by Prime India
Chennai based medical tourism and healthcare recruitment company Prime India Healthcare
Pvt. Ltd. is in plans to launch electronic health cards. The health card will be used todocument patient disease and health records of the patient as well as his family. The
electronic health cards that come with a USB drive would be highly beneficial for doctors to
administer the right tre with minimum loss of time.atment
Prime India is already providing the health cards to foreign clients as part of its medical
tourism business and is now eager to launch the same for Indian patients through
collaboration with hospitals, pharmacy retail chains and beauty wellness centres. The
product will be launched first in Chennai within a month and 20 other cities soon after. In 3‐4
months time it is expected to be launched in 7 cities inclusive of top metro cities and tier II
towns.
BCG Group to invest on healthcare facilities development
The healthcare division of Kochi based BCG Group; BCG Healthcare is in plans to develop 2
healthcare projects worth INR 3.35 bn. The healthcare division is eager to set up a health
village and a super specialty hospital at Ernakulam in Kochi. The healthcare village valued to
e approximately INR 2.25 bn has been specifically conceived for the aged in Kerala that
orms almost 13% of the state population.
b
f
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update September 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-september-2012 3/13
The village will be providing traditional healing, cultural facilities and a club house for
recreation. On the other hand BCG has already completed the construction of 100‐bed super
specialty hospital at Palarivattom in Kochi that is approximately valued at INR 1.1 bn. The
ealthcare village is expected to be completed by 2015 while the multispecialty hospital wille completed in 2013.
hb
LifeCell partners with Sequel Logistics
Chennai based the stem cell bank LifeCell International has entered into collaboration with
Sequel Logistics for personalized delivery service of the umbilical cord blood and tissue
samples. Sequel will aid in shipment of stem cells of new born through its partner airlines to
LifeCell's processing and storage facility in Chennai. The shipment will be completed within
24 hours from metro cities and 36 hours from non‐metro cities. The partnership has been
etched out specifically to avoid the long wait hours at airports.
ifeCell will have provision of the service throughout its country wide network in over 100L
cities and towns.
Stem cells have to be sent to the processing and storage facility within 48 hours in order to
chieve the highest quality stem cells. The partnership happens to be first of its kind which is
xpected to help LifeCell reap the benefits of a speedy transport facility.
a
e
News Update
Regulatory 92 drugs to be pulled out from OTC segment
The Drugs and Cosmetics Rules has notified a new schedule H1 to include over the counter
(OTC) drugs that Indians are gradually becoming resistant to or could become resistant to.
The H1 schedule comprises of 92 such antibiotic and anti‐tuberculosis drugs that will be
restricted and would be made available only on presentation of prescription. The Drug
Controller General has already brought the issue to the notice of Union Health Ministry that
will take upon the necessary action.
AIIMS conducting clinical trial of vivax malaria vaccine
AIIMS has been conducting clinical trail of vivax malaria vaccine for its malaria afflicted
patients. The synthetic malaria vaccination that AIIMS has been administering to its patientswas launched by a private pharmaceutical company on 25th April 2012 slated as the World
Malaria Day. The vaccine is not yet available in the open market and is being administered
only to patients admitted in AIIMS emergency. 300 such malaria afflicted patients have been
administered the vaccine, the clinical trial results of which are being kept undisclosed by the
h
ospital.
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update September 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-september-2012 4/13
Depending on the results of the trial the vaccine will be made available in government
hospitals at subsidized rates. The vaccination is expected to bring about a welcome change
for patients since the disease till date has no dependable medication.
DBT funds inStem for its research initiative
The Department of Biotechnology (DBT) will be investing INR 950 mn in collaboration with
National Centre for Biological Sciences (NCBS) and Tata Institute of Fundamental Research
for a new initiative by the Institute for Stem Cell Biology and Regenerative Medicine
(inStem).
inStem is being funded for its initiative in the area of chemical biology and molecular
therapeutics in Bengaluru. inStem – NCBS would be collaborating with UK based University
of Cambridge for carrying out research in cancer and biomedical research.
HLL initiates
fair
price
outlet
at
Government
Eye
Hospital
HLL Lifecare, a mini ratna public sector undertaking in collaboration with Kerala state
government has established a fair price ophthalmic products outlet at Regional Institute of
Ophthalmology. The outlet will be supplying products like spectacles, lenses and frames with
a rebate in the range of 20% to 60% in comparison to open market prices.
Non‐existence of any price regulation for ophthalmic products where prices are fixed as per
the private players, there was urgent need of ophthalmic products subsidization. The
company that strives to provide quality products at affordable prices will be a boon for the
poor.
News Update
Expansion Plans Wockhardt launches generic anti depressant
Wockhardt has acquired approval for marketing Bupropion HCl tablets from United States
Food & Drug Administration (US FDA). The anti depressant drug is the generic form of
Wellbutrin® SR that is marketed in the USA by GlaxoSmithKline. Following the approval,
Wockhardt plans to launch the product with immediate effect. The pharmaceutical and
iotechnology major developed the anti depressant drug technology in‐house andbmanufactured the same at its Waluj facility in Maharashtra.
The approval sums up to Wockhardt’s 6th Abbreviated New Drug Application (ANDA)
approval within a phase of 2 weeks and the generic drug happens to be one of Wockhardt’s
product based on extended‐release technology. Global rise in the number of depression
patients is facilitating companies to launch anti depressants especially generic versions that
have 2‐way benefit for pharma companies as well as patients.
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update September 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-september-2012 5/13
E-MAGIC® Plus stent forays into India
Opto Eurocor Healthcare Limited (OEHL) has launched its first Sirolimus Drug Eluting Stent
(DES), E‐MAGIC® Plus following the approval from Drug Controller General of India (DCGI).
he product launched by OECL has a choice of 2 drug coatings. The launch of the product o
Tmakes OECL one of the very few c mpanies to have dual drug coating DES product.
The stent has particularly been designed with an extra edge with soft tip technology to
provide smooth access to the lesion site ensuring minimal trauma to the vessel wall. The
newly launched product will bring relief to patients as the stent will help in reducing drug
onsumption significantly. The innovation by OEHL will help patients in India to opt for
etter products that would otherwise have to be imported.
c
b
Osmotica forms an alliance with Panacea Biotec
Wilmington based Osmotica Pharmaceutical Corp. has joined hands with Indian
biotechnology company Panacea Biotec Ltd. with the aim to launch more drugs in NorthAmerican market. The alliance will see Panacea focusing on product development and
anufacturing while Osmotica will deal in product registration, legal matters, attainingm
approvals for the drugs and preparing for launch of products in the market.
The deal that was signed on 11th Sep, 2012 will be beneficial for both the companies as both
can stimulate their business extensively. The partnership will help them in tapping the US
arket that is currently projecting an ever increasing demand for high‐quality
harmaceutical products.
m
p
Stem cell research institute to be set up in Surat
The Gujarat state health minister, Jay Narayan Vyas announced the setting up of a Stem CellResearch Institute in Surat at the 2‐day Regional Science Congress meet. The research
institute has been estimated to be approximately worth INR 1 bn and is expected to start
peration by the end of 2013. The research institute at Surat is being set up in the framework o
of Stem Cell Research at Vellore, Tamil Nadu but will be equipped with latest facilities.
Stem cell therapy known to be beneficial for treatment of wide array of critical ailments like
heart ailments, kidney disorders, blood cancer, and thalassaemia is getting prominence in
ndian medical circuit. The Surat research institute that is being financed by the health
epartment will thus be making treatments of such critical diseases accessible.
I
d
Healthcare Sector – Monthly Update
Trivitron inks
pact
with
Johari
Chennai based Trivitron Healthcare has entered into a strategic alliance with Jodhpur based
Johari Digital Healthcare to capture global medical devices market. The allies will engage
themselves in manufacture and marketing of physiotherapy, diagnostic care products and
also focus on acquiring patents in physiotherapy genre. The joint venture has been labeled as
Johari Trivitron Medical Innovations Pvt. Ltd. that would look into contract designing and
engineering of the products. The firm would also carry out contract R&D from global
partners. The venture will be established at Trivitron Research Park within IIT Madras.
7/29/2019 Healthcare Sector in India Monthly Update September 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-september-2012 6/13
The products are being designed keeping India, South and South East Asia, Middle East and
frican geographies in mind which demand cost effective high quality products. The deal will
ee Johari manufacturing the products and Trivitron dealing with its marketing and sales.
A
s
NVP invests in Thyrocare Technologies
Norwest Venture Partners (NVP) has invested INR 1.2 bn in Mumbai based Thyrocare
Technologies. As per the deal structure, the investment will bring in NVP’s managing director
ohil Chand as Thyrocare’s board member. The investment will initiate Thyrocare to exploreS
global markets for its medical diagnostic products.
Thyrocare has its presence through a network of 20,000 service centers across 1,000 cities
nd towns, and 100,000 doctors through 600 franchisees. Its wide presence is expected to be
ccelerated further to reach globally with the new investment.
a
a
Industry Expert Speak
DBT funds inStem for its research initiative - Professor Ashok Venkitaraman, Ursula Zoellner, professor of Cancer Research, University of Cambridge and director, Medical Research Council Cancer Cell Unit “The research will now improve our fundamental understanding of the cellular abnormalities
hat cause human diseases like cancer but also to translate this information for the benefit of
atients”
t
p
Trivitron inks
pact
with
Johari
-Dr. GSK Velu, Founder and MD of Trivitron Healthcare
This partnership is an important step towards taking Indian medical technology solutions at
global level."
"
a
Transaction Detail (Jul – Sep 2012)
Date Buyer Target Deal Size
(INR mn) % stake Deal Status
Type of
Transaction
27th Sep
2012
Norwest Venture
Partners
Thyrocare
Technologies1200 10% Completed Private Equity
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update September 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-september-2012 7/13
12th Sep2012
Avigo CapitalPartners
Super ReligareLaboratories
2,916.79 N.A. Planned Private Equity
12th Sep2012
IndoUS VenturePartners
Vyome
Biosciences Pvt Ltd.
185 N.A. Planned Private Equity
11th Sep2012
Norwest VenturePartners
ThyrocareTechnologies
Ltd1166.71 10% Planned Private Equity
5th Sep
2012
Norwest
Venture
Partners
NationWide
PrimaryHealthcare
Services Pvt.Ltd.
250 N.A. Completed Private Equity
3 g0th Au2012
Hospira
OrchidChemicals and
P sharmaceutical
Ltd.Penicillin and
Penem APIbusiness
11125.89 100% Completed Acquisition
2 g9th Au2012
PfizerStrides ArcolabInjectable Drug
Unit
94600 100% Planned Acquisition
23 grd Au
2012
India
InnovationFund
&
Indian AngelNetwork
Consure
MedicalN.A. N.A. Completed Private Equity
21st Aug2012
India EquityPartners
Axiss Dental N.A. N.A. Planned Private Equity
1 g3th Au2012
Somerset IndusCapital
Partners
Express ClinicsPvt. Ltd.
N.A. N.A. Completed Private Equity
1 g3th Au
2012
Goldman Sachs&
New EnterpriseAssociates
Nova MedicalCentres
2969.35 N.A. Completed Private Equity
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update September 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-september-2012 8/13
1 g3th Au2012
Sun
PharmaceuticalIndustries Ltd.
Taro
PharmaceuticalIndustries
32,552.9 34% Planned M&A
30th Jul2012
Sequoia Capital
Practo
TechnologiesPvt. Ltd.
250 N.A. Completed Private Equity
2 l3rd Ju2012
Signet Healthcare
Partners
ClarisLifesciences
227.6 2.20 Completed Private Equity
19th Jul
2012
Medtronic Inc.Trivitron
Healthcare
5498.70 N.A. Planned Private Equity
13th Jul2012
EvolvenceIndia Life
Sciences Fund
Dr. Agarwal'sHealthcare
600 25 Completed Private Equity
4th Jul
2012
RajasthanVenture Capital
Fund
International
OncologyServices Pvt.
Ltd.
200 N.A. Completed Private Equity
Annual Financial Results – Revenue (INR mn) – Major Healthcare
Companies Companies FY ’09 FY ’10 FY ’11 FY’ 12
Biocon Ltd. 16,492.50 23,932.70 27,947.70 21,483.0
Blue Star Ltd. 25,026.2 25,249.7 29,536.8 27,888.5
Cadila Healthcare Ltd. 29,066.00 35,780.00 44,671.00 50,899.7
Cipla Ltd. 52,876.20 56,704.00 63,850.70 68,477.0
Dabur India Ltd. 28,122.40 33,958.00 40,817.40 52,832.0
Dr. Reddy’s Laboratories(DRL)
69,441.00 70,277.00 74,693.00 96,737.4
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update September 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-september-2012 9/13
GlaxosmithKlineConsumer Healthcare
Ltd.19,757.6 23,693.3 27,688.6 28,857.3
Glenmark
Pharmaceuticals Ltd. 21,241.20 25,291.30 29,490.70 40,206.4
Jubilant life Sciences Ltd. 35,491.00 38,047.80 34,484.40 42,539.5
Lupin Ltd. 38,508.30 48,318.10 57,851.90 70,829.1
Nestle India Ltd. 51,395.5 62,609.4 74,994.6 77,409.0
Opto Circuits (India) Ltd. 8,185.197 10,775.826 15,855.631 23,568.543
Piramal Healthcare Ltd. 32,478.20 36,276.30 25,157.70 20,838.3
Ranbaxy LaboratoriesLtd. 75,970.40 89,607.70 101,614.1 117,153.2
Siemens India Ltd. 93,070.2 96,272.4 119,718.1 124,657.9
Strides Arcolab Ltd. 13,101.6 16,958.4 25,245.2 25,645.1
Sun Pharmaceuticals
Industries Ltd.42,723.00 38,086.30 57,214.30 80,056.6
Torrent Pharmaceuticals
Ltd.16,306.60 19,160.40 22,264.80 26,959.2
Wockhardt Ltd. 3,6294.4* 36,477.60 37,633.50 46,138.0
Annual Financial Results – Income (INR mn) - Major Healthcare
Companies
Companies F Y ’09 FY ’10 FY ’11 FY’ 12
Biocon Ltd. 931.2 2,932.40 3,675.20 3,384.0
Blue Star Ltd. 1,802.9 2,114.9 1,609.6 ‐1,051.0
Cadila Healthcare Ltd. 3,031.00 5,051.00 7,110.00 6,525.9
Cipla Ltd. 7,710.20 10,825.90 9,895.70 11,442.4
Dabur India Ltd. 3,905.00 5,010.80 5,685.70 6,449.0
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update September 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-september-2012 10/13
Dr. Reddy’s Laboratories(DRL)
‐5,168.00 1,068.00 11,040.00 14,262.1
GlaxoSmithKline Consumer
Healthcare Ltd.2,327.8 2,998.5 3,552.1 3,765.6
Glenmark Pharmaceuticals
Ltd.1,916.60 3,244.70 4,532.10 4,603.5
Jubilant life Sciences Ltd. 2,831.80 4,214.60 2,297.20 145.6
Lupin Ltd. 5,015.40 6,816.30 8,625.50 8,676.5
Nestle India Ltd. 6,550.0 8,186.6 9,615.5 9,815.7
Opto Circuits (India) Ltd. 2,087.3 2,603.0 3,672.5 5,718.8
Piramal Healthcare Ltd. 3,162.50 4,819.00 128,833.60 1,115.0
Ranbaxy Laboratories Ltd. 2,964.90 14,967.50 ‐28,997.3 ‐19,573.5
Siemens India Ltd. 7,046.0 7,577.7 8,677.5 7,300.6
Strides Arcolab Ltd. 1,096.80 1,224.50 2,244.8 8,258.4
Sun PharmaceuticalsIndustries Ltd.
18,177.30 13,510.80 18,160.60 25,872.5
Torrent Pharmaceuticals Ltd. 1,843.70 2,312.00 2,701.70 2,840.4
Wockhardt Ltd. ‐4,355.4* ‐9,804.20 905.2 3,427.1
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update September 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-september-2012 11/13
Quarterly Financial Results – Revenue (INR mn) – Major Healthcare
Companies Companies
Jul-Sep
2011
Oct -Dec
2011
Jan-Mar
2012
Apr-Jun
2012
Biocon Ltd. 5,084.40 5,171.90 5,892.2 5,770.0
Blue Star Ltd. N.A. 5,896.9 N.A. N.A.
Cadila Healthcare Ltd. 12 0,196.4 13,524.60 14 .9,633 15 .0,161
Cipla Ltd. N.A. 17,580.00 N.A N.A.
Dabur India Ltd. 12,623.30 14,526.80 13,858.3 14,620.0
Dr. Reddy’s Laboratories
(DRL)22,678.00 27,692.00 26,584.0 25,406.0
GlaxoSmithKline ConsumerHealthcare Ltd.
7,200.7 6,854.0 8,608.7 7,869.6
Glenmark Pharmaceuticals
Ltd.10,554.50 10,310.90 10,751.2 10,404.1
Jubilant life Sciences Ltd. 10,480.80 10,871.70 12,235.9 12,358.9
Lupin Ltd. 17,416.6 17,917.0 20,063.7 22,191.5
Nestle India Ltd. 19,631.00 19,633.2 20,558.7 19,865.8
Opto Circuits (India) Ltd. 5,620.4 6,112.9 6,627.0 7,150.6
Piramal Healthcare Ltd. 4,775.80 5,518.30 8,858.0 7,102.9
Ranbaxy Laboratories Ltd. 20 .3,955 37 .1,923 36,954.0 31 .6,740
Siemens India Ltd. N.A. N.A. 37 2601.43 N.A.
Strides Arcolab Ltd 7,693.10 6,864.7 5,274.7 5,082.9
Sun PharmaceuticalsIndustries Ltd. 18,946.00 21,451.30 23,299.3 26,581.4
Torrent Pharmaceuticals Ltd 6,833.3 6,965.9 6,686.8 7,356.0
Wockhardt Ltd. 11,105.30 12,086.70 12,413.90 14,258.2
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update September 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-september-2012 12/13
Quarterly Financial Results – Income (INR mn) - Major Healthcare
Com anies
Companies
Jul-Sep
2011
Oct -Dec
2011
Jan-Mar
2012
Apr-Jun
2012
Biocon Ltd. 857.0 848.50 978.0 790.0
Blue Star Ltd. N.A. (327.6) N.A. N.A.
Cadila Healthcare Ltd. 1,0 026.8 1,492.10 1, 8708. 1, 9947.
Cipla Ltd. N.A. 2,699.10 N.A. N.A.
Dabur India Ltd. 1,738.6 1,728.20 1,705.1 1,494.0
Dr. Reddy’s Laboratories
(DRL)3,078.0 5,130.0 3,427.0 3,360.0
GlaxoSmithKline ConsumerHealthcare Ltd.
1,030.3 591.0 1,319.7 1,066.0
Glenmark Pharmaceuticals
Ltd.558.6 461.20 1,482.7 782.8
Jubilant life Sciences Ltd. 793.6 ‐783.90 ‐635.3 50.1
Lupin Ltd. 2,668.70 2,350.60 1,556.4 2,803.9
Nestle India 2,611.80 2,308.30 2,757.3 2,459.7
Opto Circuits (India) Ltd. 1,210.6 1,250.8 2,093.5 1,380.2
Piramal Healthcare Ltd. 524.3 85.2 ‐386.8 40.8
Ranbaxy Laboratories Ltd. ‐4,645.8 ‐29 .7,827 12,467.6 ‐5,857.3
Siemens India Ltd. N.A. N.A. 3,040.0 N.A.
Strides Arcolab Ltd 464.7 684.1 6,420.7 904.8
Sun Pharmaceuticals
Industries Ltd.5,977.4 6,683.0 8202.1 7,955.5
Torrent Pharmaceuticals Ltd 999.9 831.8 ‐16.5 1,018.5
Wockhardt Ltd. 1,275.80 2,128.10 ‐1,916.4 3,779.7
* denotes a change in financial year
Healthcare Sector – Monthly Update
7/29/2019 Healthcare Sector in India Monthly Update September 2012
http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-september-2012 13/13
Events Calendar
Pre-Conference Workshops & International
Confer E-BASED HEALTHCARE ence on EVIDENC
Date: 6
th – 8enue:
th Oct, 2012V India International Centre, New DelhiOrganize All India
(AIIMS)
r: Clinical Epidemiology Unit of Institute of Medical Sciences
Website: ht tp://www.isehcon2012.com d
Contact 434
Contact Person: Dr. Kameshwar Prasa6588
Fax No. 8641
No.: +91‐11‐26594436/2: +91‐11‐26588663/2658
Email: [email protected]
Pharm mpliance Summit 2012 a Legal & Co
Date: 5
th OVenue: H mbai
ct, 2012
Organize
otel Holiday Inn, Mur: Lex Witness
Website: www.plcs2012.com Contact Person: 01143440000Contact No. : +91‐8800841600Email: [email protected]
Research on India (ROI) is a leading source for market research on various sectors in India
hat offers premium research content from worldwide publishers of market researcht reports.
Contact us:
mW: https://www.researchonindia.co
; International: +91 (33) 4027 6214/5T
E
: India (Toll Free): 1800 102 1133
Connect with Us
Disclaimer: This monthly update is published for general information only based on press articles and company releases. Research on India has not independently verified any of information and is not responsible for any loss or damage arising from use of this document.
Healthcare Sector – Monthly Update